---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-099200"
form_type: "8-K"
ticker: null
cik: "0000786947"
company_name: "ACURA PHARMACEUTICALS, INC"
filed_at: "2026-08-20T19:26:03+00:00"
generated_at: "2026-08-20T19:27:12.380384+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Acura takes $200K loan from Abuse Deterrent Pharma; warns of bankruptcy risk without more funding by Sept 2026

## Summary
- Received $200,000 loan from AD Pharma on 8/14/2026; total principal now $11,094,279 with ~$1,290,000 accrued interest.
- Loan bears 5.25% interest, rising to 7.5% on overdue amounts; proceeds used for day-to-day operations.
- Without additional financing by late-September 2026, may furlough staff, scale back operations, or seek bankruptcy protection.
- Company warns of possible complete loss of shareholder value if operations must cease.
- Note and accrued interest currently due/negotiable by December 31, 2026.

## SEC filing metadata
- accession: 0001104659-26-099200
- form_type: 8-K
- cik: 0000786947
- company_name: ACURA PHARMACEUTICALS, INC
- filed_at: 2026-08-20T19:26:03+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/786947/000110465926099200/0001104659-26-099200-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/786947/000110465926099200/tm2623715d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-099200
- JSON: https://secwatch.observer/filing/0001104659-26-099200.json
- Plain text: https://secwatch.observer/filing/0001104659-26-099200.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.